OKYO Pharma Correlations
OKYO Stock | USD 1.01 0.03 2.88% |
The current 90-days correlation between OKYO Pharma and Bionomics Limited is -0.18 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma Ltd moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
OKYO Pharma Correlation With Market
Good diversification
The correlation between OKYO Pharma Ltd and DJI is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding OKYO Pharma Ltd and DJI in the same portfolio, assuming nothing else is changed.
OKYO |
Moving against OKYO Stock
0.38 | A | Agilent Technologies | PairCorr |
0.36 | DOMH | Dominari Holdings | PairCorr |
0.4 | CDTTW | Conduit Pharmaceuticals | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between OKYO Stock performing well and OKYO Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze OKYO Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
BNOEF | 23.90 | 4.68 | 0.15 | (0.99) | 19.78 | 86.34 | 181.72 | |||
CADL | 3.17 | (0.68) | 0.00 | (0.34) | 0.00 | 6.70 | 26.59 | |||
ANEB | 4.90 | (0.11) | (0.01) | 0.02 | 7.16 | 8.61 | 76.00 | |||
CINGW | 11.82 | 1.49 | 0.08 | (0.82) | 13.22 | 36.81 | 95.43 | |||
UNCY | 4.27 | 1.11 | 0.20 | 0.86 | 4.19 | 10.26 | 29.22 | |||
QNRX | 6.38 | 0.81 | 0.11 | 0.87 | 6.50 | 24.68 | 74.46 | |||
CDIO | 6.26 | (0.47) | (0.01) | 0.01 | 6.68 | 14.81 | 57.04 | |||
VRAX | 5.59 | (0.99) | 0.00 | 2.51 | 0.00 | 9.65 | 61.28 | |||
PXMD | 3.75 | (1.09) | 0.00 | (1.18) | 0.00 | 7.63 | 23.71 |
OKYO Pharma Corporate Management
Michael Beck | Founder | Profile | |
Keeren Shah | Chief Officer | Profile | |
PharmD Clementi | Chief Officer | Profile | |
Rajkumar Patil | Chief Officer | Profile | |
Gary Jacob | CEO Director | Profile |